[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Pap et al., 2001 - Google Patents

Delivery of antisense constructs and ribozymes to inhibit cartilage destruction in the SCID mouse model of RA

Pap et al., 2001

View PDF
Document ID
14488216628157009623
Author
Pap T
Schedel J
Müller-Ladner U
Gay R
Zacharias W
Gay S
Publication year
Publication venue
Arthritis Research & Therapy

External Links

Snippet

Objectives: Local gene transfer to bone and adjacent tissues offers promise in cases of bone healing disorders such as segmental bone defects, non-unions, and aseptic loosening of endoprotheses. Method and results: Studies in which osteoinductive genes have been …
Continue reading at link.springer.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48776—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form forms of ingredients not provided for by groups A61K47/48784 - A61K47/48992, e.g. cells, cell fragments, viruses, ghosts, red blood cells, viral vectors having the pharmacologically or therapeutically active agent complexed or covalently linked to, or being themselves modified by complexation or covalent linkage by a modifying agent

Similar Documents

Publication Publication Date Title
Gelse et al. Fibroblast‐mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer
JPH08508415A (en) Systemic gene therapy for connective tissue disease
Hernigou Autologous bone marrow grafting of avascular osteonecrosis before collapse
Cournil et al. Overexpression and induction of heat shock protein (Hsp) 70 protects in vitro and in vivo from mono-iodoacetate (MIA)-induced chondrocytes death
Ghivizzani et al. Gene therapy approaches for treating rheumatoid arthritis
Bakker et al. Inflammation-inducible intra-articular production of human IL-1 receptor antagonist results in a more efficient inhibition of collagen-induced arthritis than does constitutive expression of the same transgene
Mountz et al. AKT regulates TNF-alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts
Evans et al. Transfer and intra-articular expression of the IL-1Ra cDNA in human rheumatoid joints
van de Loo et al. Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?
Grigolo et al. Evidence for re-differentiation of human chondrocytes seeded on a hyaluronan derivative scaffold
Bolon et al. Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease
Chernajovsky et al. Engineering T cells and molecules for targeting joints and inflammation
Gouze-Decaris et al. In vitro and in vivo gene delivery using a lentiviral vector
Schett et al. Adenoviral-based overexpression of TIMP-1 reduces tissue damage in the joints of TNF-alpha transgenic mice
Müller-Ladner et al. Double and triple gene transfer in arthritis
Jüllig et al. Gene therapy in orthopaedic surgery: the current status
Jennings et al. Adeno-associated virus preferentially transduces human compared to mouse synovium
Robbins et al. Update on the contralateral effect in rabbit and mouse models
Robbins et al. Viral, nonviral and peptide-mediated intra-articular transfer of genes and proteins
Redlich et al. Therapeutic targeting of osteoclasts by osteoprotegerin and bisphosphonates leads to a reduction of TNFalpha-mediated bone resorption
Scherman et al. High efficiency intramuscular plasmid electrotransfer: application for sustained plasmatic secretion of cytokines
Pap et al. Delivery of antisense constructs and ribozymes to inhibit cartilage destruction in the SCID mouse model of RA
Bakker et al. Using a tropism-modified adenoviral vector for the intra-articular production of IL-1 receptor antagonist results in a more efficient inhibition of collagen-induced arthritis than does a conventional Ad5 vector
Baltzer Viral gene transfer for bone healing
Tarner et al. Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4